Diaceutics (DXRX) RNS Announcements

Add to Alert list
Date Time Source Announcement
19 Dec 2024 08:09 AM
RNS
Holding(s) in Company
17 Dec 2024 10:46 AM
RNS
Holding(s) in Company
17 Dec 2024 07:00 AM
RNS
Diaceutics Wins New $5.1m Contract
10 Dec 2024 03:14 PM
RNS
Holding(s) in Company
05 Dec 2024 07:00 AM
RNS
Awarded UK Research Institute Grant Funding of £1m
03 Dec 2024 02:24 PM
RNS
Total Voting Rights
28 Nov 2024 07:00 AM
RNS
Expansion of US Commercial Activities
05 Nov 2024 07:00 AM
RNS
Capital Markets Webinar
04 Nov 2024 07:00 AM
RNS
Holding(s) in Company
30 Oct 2024 02:58 PM
RNS
PDMR Shareholding/Share Incentive Plan
29 Oct 2024 10:27 AM
RNS
Board Change Update
25 Oct 2024 07:00 AM
RNS
Issue of Share Options/PDMR Shareholdings
24 Oct 2024 12:53 PM
RNS
Cancellation of Share Premium Account
15 Oct 2024 07:00 AM
RNS
Diaceutics Announces Key Leadership Appointment
07 Oct 2024 01:19 PM
RNS
Holding(s) in Company
07 Oct 2024 07:00 AM
RNS
Block Listing Return
02 Oct 2024 07:00 AM
RNS
PDMR Shareholding/Share Incentive Plan
01 Oct 2024 07:00 AM
RNS
Board Changes
17 Sep 2024 07:00 AM
RNS
H1 2024 Results - Continued Performance & Growth
09 Sep 2024 07:00 AM
RNS
Notice of Results & Presentations
02 Sep 2024 07:00 AM
RNS
Appointment of Nominated Adviser and Broker
30 Aug 2024 03:45 PM
RNS
PDMR Shareholding/Share Incentive Plan
27 Aug 2024 07:00 AM
RNS
Diaceutics Launches Enhanced Rare-Disease Offering
19 Aug 2024 07:00 AM
RNS
Enterprise Partnership and Launch of PMx
05 Aug 2024 07:00 AM
RNS
Presenting at Canaccord Genuity Growth Conference
29 Jul 2024 06:09 PM
RNS
PDMR Shareholding/SIP and TVR
29 Jul 2024 07:00 AM
RNS
Issue of Share Options/PDMR Shareholdings
23 Jul 2024 07:05 AM
RNS
Board Changes
23 Jul 2024 07:00 AM
RNS
Revenue growth of 24% in H1 with 55% now recurring
11 Jul 2024 07:00 AM
RNS
Senior Management Appointments
01 Jul 2024 07:00 AM
RNS
PDMR Shareholding/SIP and Total Voting Rights
24 Jun 2024 01:15 PM
RNS
Result of AGM
13 Jun 2024 07:00 AM
RNS
"Precision Medicine in Oncology " Virtual Event
06 Jun 2024 07:00 AM
RNS
Diaceutics - Capital Markets Event
29 May 2024 08:00 AM
RNS
Notice of AGM and Posting of Annual Report
29 May 2024 08:00 AM
RNS
Notice of AGM and Posting of Annual Report
28 May 2024 07:00 AM
RNS
Data to be Presented at 2024 ASCO Annual Meeting
24 May 2024 03:01 PM
RNS
PDMR Shareholding/SIP and Total Voting Rights
23 May 2024 07:00 AM
RNS
Director / PDMR Shareholding
21 May 2024 07:00 AM
RNS
Revenue growth of 22% & order book growth of 57%
16 May 2024 07:00 AM
RNS
Two New Enterprise-Wide Engagements
14 May 2024 07:00 AM
RNS
Diaceutics - Capital Markets Event
01 May 2024 07:00 AM
RNS
Notice of Results & Presentations
30 Apr 2024 07:00 AM
RNS
PDMR Shareholding/SIP and TVR
09 Apr 2024 07:00 AM
RNS
Appointment of Amie Mc Neice as VP of Marketing
05 Apr 2024 01:40 PM
RNS
Block Listing Return
03 Apr 2024 07:00 AM
RNS
PDMR Shareholding/Share Incentive Plan
02 Apr 2024 07:00 AM
RNS
Director/PDMR/PCA Shareholding & TR1
21 Mar 2024 07:00 AM
RNS
Significant upgrade to Diaceutics' DXRX platform
19 Mar 2024 07:00 AM
RNS
Diaceutics forms landmark industry Forum

Diaceutics PLC, a global leader in the field of precision medicine, holds a significant position on the London Stock Exchange (LSE). As part of the dynamic financial ecosystem facilitated by the London Stock Exchange Group (LSEG), Diaceutics PLC contributes to the global financial landscape.

The Diaceutics share price and DXRX share price are key indicators of the company's market performance. These metrics are closely monitored by investors to assess the company's financial health and make informed investment decisions.

Founded in 2005, Diaceutics PLC is headquartered in Belfast, United Kingdom. The company has been a pioneer in the field of diagnostic testing, collating large amounts of laboratory, patient, claims, and payor data which it uses to deliver diagnostic testing strategies to its clients. Over the years, Diaceutics PLC has amassed a set of data from over 52,515 laboratories, showing disease volumes and 481 million de-identified patient records globally in 53 countries. This data collection has allowed the company to accumulate a proprietary database of laboratory capabilities across the industry.

Diaceutics PLC provides services to 39 global pharmaceutical companies and is focused on optimising its clients’ strategies for the development and launch of precision medicines. Precision medicines are a class of drug tailored to individual patient groups dependent on molecular or genetic factors of the individual. Today, they are used for treatment in oncology as well as other disease areas such as multiple sclerosis and rheumatoid arthritis.

Being listed on the LSE, Diaceutics PLC is part of the vibrant financial ecosystem facilitated by the London Stock Exchange Group (LSEG). LSEG, a leading global financial markets infrastructure and data provider, plays a crucial role in supporting the financial stability and growth of communities and economies globally.

In conclusion, Diaceutics PLC, with its strategic focus on precision medicine and its status as a company listed on the LSE, represents a noteworthy entity in the financial markets landscape facilitated by LSEG. Its share price, referred to as both Diaceutics share price and DXRX share price, are key considerations for investors, reflecting the company's market performance. As part of the vibrant LSEG ecosystem, Diaceutics PLC contributes to the broader financial markets infrastructure, underscoring its significance in the global financial community.

UK 100

Latest directors dealings